Aviragen Therapeutics (AVIR) is Initiated by Ladenburg Thalmann to Buy

Aviragen Therapeutics (AVIR) was Initiated by Ladenburg Thalmann to “Buy”. Ladenburg Thalmann advised their investors in a research report released on Sep 21, 2016.

Many Wall Street Analysts have commented on Aviragen Therapeutics. H.C. Wainwright Initiated Aviragen Therapeutics on Jul 13, 2016 to “Buy”, Price Target of the shares are set at $5.

Aviragen Therapeutics

Leave a Reply

Aviragen Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aviragen Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.